Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: Data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) Program, 2007 by Hawser, Stephen P. et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2009, p. 3280–3284 Vol. 53, No. 8
0066-4804/09/$08.000 doi:10.1128/AAC.00426-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.
Emergence of High Levels of Extended-Spectrum--Lactamase-Producing
Gram-Negative Bacilli in the Asia-Pacific Region: Data from the Study
for Monitoring Antimicrobial Resistance Trends
(SMART) Program, 2007
Stephen P. Hawser,1* Samuel K. Bouchillon,2 Daryl J. Hoban,2 Robert E. Badal,2
Po-Ren Hsueh,3 and David L. Paterson4
IHMA, 1066 Epalinges, Switzerland1; International Health Management Associates, Inc., Schaumburg, Illinois 60173-38172; Departments of
Laboratory Medicine and Internal Medicine, National Taiwan University Hospital, National Taiwan University
College of Medicine, Taipei, Taiwan3; and University of Queensland, Brisbane, Australia4
Received 30 March 2009/Returned for modification 29 April 2009/Accepted 30 May 2009
Of 3,004 gram-negative bacilli collected from intra-abdominal infections in the Asia-Pacific region during
2007, 42.2% and 35.8% of Escherichia coli and Klebsiella spp., respectively, were extended-spectrum -lactamase
(ESBL) positive. Moreover ESBL rates in India for E. coli, Klebsiella pneumoniae, and Klebsiella oxytoca were
79.0%, 69.4%, and 100%, respectively. ESBL-positive E. coli rates were also relatively high in China (55.0%) and
Thailand (50.8%). Ertapenem and imipenem were the most active drugs tested, inhibiting over 90% of all
species, including ESBL-positive isolates with the exception of Pseudomonas aeruginosa isolates (<90% sus-
ceptible to all study drugs) and ESBL-positive Klebsiella pneumoniae isolates (<90% susceptible to all study
drugs except imipenem). Quinolones achieved 90% inhibition levels only against ESBL-negative K. pneumoniae
and ESBL-negative K. oxytoca. A decline in ampicillin-sulbactam activity was noted, with only 34.5% of all
Enterobacteriaceae inhibited in this study.
Gram-negative bacilli (GNB) continue to be an important
cause of health care-associated infections (8, 15). They are a
common cause of sepsis, pneumonia, urinary tract infection,
postsurgical infections in acute care hospitals, and intra-ab-
dominal infections (16). Antimicrobial resistance among these
bacilli is increasing on a worldwide basis, especially resistance
against -lactam antibiotics due to the development of -lac-
tamase enzymes, which can hydrolyze the -lactam ring of such
antibiotics (1). Various types of -lactamases can confer resis-
tance to expanded-spectrum cephalosporins, including chro-
mosomally mediated -lactamases, extended-spectrum -lac-
tamases (ESBLs), metallo--lactamases, and KPCs. ESBLs are
known to confer resistance to all -lactam drugs, but organisms
typically remain susceptible to carbapenems (4, 12).
Large-scale surveillance studies demonstrate that the vast
majority of ESBL-producing Escherichia coli and Klebsiella
pneumoniae isolates, among others, are susceptible to carbap-
enems (9, 11, 17). However, antibiotic resistance in GNB is
evolving globally, with different levels of regional resistance
that can vary significantly. It is therefore increasingly important
to monitor susceptibility trends in various regions of the world
over time to detect, define, track, and communicate those
trends so that effective therapeutic measures can be deter-
mined and customized to meet local needs.
The Study for Monitoring Antimicrobial Resistance Trends
(SMART) program monitors the activity of ertapenem, imi-
penem, amikacin, cefepime, cefotaxime, cefoxitin, ceftazidime,
ceftriaxone, ciprofloxacin, levofloxacin, ampicillin-sulbactam,
and piperacillin-tazobactam against GNB from intra-abdomi-
nal infections (IAI). This program has been ongoing since 2002
in most regions of the world, with nearly 120 hospitals partic-
ipating in 2008. This report reviews the most current data from
the SMART program from the Asia-Pacific region for isolates
collected throughout 2007.
(Parts of this study were presented as posters at the joint
48th Annual Interscience Conference on Antimicrobial Agents
and Chemotherapy/46th Annual Meeting of the Infectious Dis-
eases Society of America, 2008 [2] and at the 7th International
Symposium on Antimicrobial Agents and Resistance, 2009
[3].)
MATERIALS AND METHODS
All isolates were derived from IAI. Only one isolate per patient was accepted
into the study. Gram-negative aerobic and facultative bacteria were cultured
from specimens from intra-abdominal body sites, e.g., appendix, peritoneum,
colon, bile, pelvis, and pancreas. The majority of intra-abdominal specimens
were obtained during surgery, though some paracentesis specimens were also
accepted. Isolates from blood, urine, and perirectal abscesses were excluded.
Overall, 3,004 clinical isolates from 35 laboratories in the following 11 locations
in the Asia-Pacific region (numbers of laboratories are in parentheses) were
collected and tested in 2007: Australia (1), China (6), Hong Kong (1), India (9),
South Korea (2), New Zealand (2), Philippines (1), Singapore (2), Taiwan (7),
Thailand (2), and Vietnam (2). Isolates were identified to the species level and
tested at each site. Development of a centralized database of study results was
managed by International Health Management Associates, Inc., located in
Schaumburg, IL. All organisms were deemed clinically significant by local par-
ticipant criteria. Isolate inclusion was independent of antimicrobial use, age, or
gender. All sites identified each study isolate utilizing local laboratory methods.
MICs were determined using dehydrated MicroScan broth microdilution pan-
els manufactured by Siemens Medical Solutions Diagnostics (West Sacramento,
CA) by following Clinical and Laboratory Standards Institute (CLSI) guidelines
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(7). All antimicrobial agents were supplied by the panel manufacturer. The
following antimicrobial agents, with their dilution ranges (expressed in g/ml),
were included on the panels: ertapenem, 0.03 to 4; imipenem, 0.06 to 8;
cefepime, 0.5 to 32; ceftazidime, 0.5 to 128; ceftazidime-clavulanic acid, 0.12 to
16; cefoxitin, 2 to 16; ciprofloxacin, 0.25 to 2; amikacin, 4 to 32; levofloxacin, 0.5
to 4; cefotaxime, 0.5 to 128; cefotaxime-clavulanic acid, 0.12 to 16; piperacillin-
tazobactam, 2 to 64 (piperacillin) and 4 (tazobactam); ampicillin-sulbactam, 2 to
16 (ampicillin) and 2 (sulbactam); and ceftriaxone, 1 to 32. MIC interpretive
criteria followed published guidelines established by the CLSI (6).
E. coli, K. pneumoniae, and Klebsiella oxytoca strains were classified as ESBL
producers if there was at least an eightfold reduction (i.e., three doubling dilu-
tions) of the MIC for ceftazidime or cefotaxime tested in combination with
clavulanic acid versus their MICs when either drug was tested alone (7). Quality
control (QC) testing was done by each testing site on each day of testing using the
CLSI-recommended QC strains E. coli ATCC 25922, K. pneumoniae ATCC
700603 (positive ESBL control), and Pseudomonas aeruginosa ATCC 27853. All
participating labs used the same MIC panels manufactured by Siemens Medical
Solutions Diagnostics and performed susceptibility testing and QC testing by the
CLSI protocol as described in the MicroScan package insert. QC testing was
performed each time a laboratory carried out batch testing of isolates. Only data
from test days for which all pertinent CLSI-recommended QC results were in
control were included in the database. Results were included in the analysis only
when corresponding QC isolates tested within the acceptable range according to
CLSI guidelines (6).
RESULTS
Of the 3,004 GNB isolates collected, 82% were represented
by seven species: E. coli (n  1,368), K. pneumoniae (n  528),
P. aeruginosa (n  245), Enterobacter cloacae (n  150), En-
terobacter aerogenes (n  65), Proteus mirabilis (n  61), and
Citrobacter freundii (n  51). Fifty-eight other species com-
prised the other 18% of the isolates. The most commonly
isolated organism was E. coli, for which 578 of the 1,368 iso-
lates (42.2%) were ESBL positive. Also ESBL positive were
35.8% of the K. pneumoniae isolates. Furthermore, although
the number of K. oxytoca isolates was relatively small (n  51),
22 (43.1%) were ESBL positive.
Table 1 and Fig. 1 show the distribution of ESBL isolates by
location. While ESBL rates for the Asia-Pacific region as a
whole were relatively high, several countries exhibited ESBL
rates that were strikingly higher than 50%. For example, rates
for India for ESBL-positive E. coli, K. pneumoniae, and K.
oxytoca were 79.0%, 69.4%, and 100%, respectively. Further-
more, of the nine sites in India, none had an ESBL-positive
rate for E. coli of less than 54.5% and the highest rate was
94.1% (data not shown). ESBL-positive E. coli rates were also
high in China (55.0%) and Thailand (50.8%), making ESBL-
positive isolates more common than ESBL-negative ones in all
three countries. Furthermore, Thailand also exhibited rela-
tively high rates of ESBL-positive K. pneumoniae isolates,
whereby nearly one-half (45.5%) of isolates were ESBL posi-
tive (Fig. 1). The lowest rates of ESBL-positive isolates ap-
peared in Australia and New Zealand; however, the numbers
of K. pneumoniae and K. oxytoca isolates in these two countries
were relatively small.
Table 2 describes the antimicrobial susceptibilities of the
eight most commonly isolated organisms (those with n  50),
including ESBL-positive isolates of E. coli, K. pneumoniae, and
K. oxytoca. The carbapenems, ertapenem and imipenem, were
consistently the most active agents against all strains, with the
exception of P. aeruginosa strains, for which 71% of isolates
were susceptible to imipenem. The most active antipseudomo-
nal antibiotic was amikacin, to which 85% of isolates were
susceptible, followed by piperacillin-tazobactam (81% suscep-
tible). The most active of the noncarbapenem antibiotics was
generally amikacin: susceptibility of all organisms ranged from
73 to 100%. For all other agents, susceptibilities were typically
considerably lower. Ampicillin-sulbactam exhibited notably
poor in vitro activity against all species in this study (Table 1).
The susceptibilities to ertapenem and imipenem of non-
ESBL-producing isolates ranged from 94 to 100% and 97 to
100%, respectively. ESBL-negative E. coli isolates exhibited
100% susceptibility to ertapenem and imipenem, and these
drugs maintained most of their activity against ESBL-positive
E. coli, with susceptibilities of 96% and 98%, respectively (Ta-
ble 2). Furthermore, against ESBL-negative K. pneumoniae,
ertapenem and imipenem exhibited susceptibilities of 99 and
100%, respectively. It is noteworthy that ertapenem exhibited
marginally weaker activity against ESBL-positive K. pneu-
moniae, with 86% of isolates being susceptible. With imi-
penem, the susceptibility of ESBL-positive K. pneumoniae was
TABLE 1. Frequency of ESBL-positive E. coli, K. pneumoniae, and K. oxytoca: location-specific data from the Asia-Pacific region during 2007
Location
No. of isolates of:
Total no. (%) of
ESBL isolatesE. coli that were: K. pneumoniae that were: K. oxytoca that were:
ESBLa ESBL ESBLa ESBL ESBLa,b ESBL
Australia 1 (7.7) 12 0 (0) 3 0 (0) 0 1 (6.3)
China 158 (55.0) 129 25 (27.5) 66 1 (25.0) 3 184 (48.2)
Hong Kong 8 (17.8) 37 0 (0) 0 0 (0) 0 8 (17.8)
India 264 (79.0) 70 77 (69.4) 34 15 (100) 0 356 (77.4)
South Korea 10 (22.7) 34 12 (32.4) 25 1 (25.0) 3 23 (27.1)
New Zealand 3 (3.2) 91 1 (7.1) 13 1 (20.0) 4 5 (4.4)
Philippines 9 (17.0) 44 8 (40.0) 12 0 (0) 2 17 (22.7)
Singapore 17 (33.3) 34 12 (37.5) 20 0 (0.0) 1 29 (34.5)
Taiwan 33 (12.7) 227 30 (18.3) 134 2 (14.3) 12 65 (14.8)
Thailand 33 (50.8) 32 15 (45.5) 18 0 (0) 2 48 (48.0)
Vietnam 42 (34.4) 80 9 (39.1) 14 2 (50.0) 2 53 (35.6)
Total 578 (42.2) 790 189 (35.8) 339 22 (43.1) 29 789 (40.5)
a Percentages are in parentheses.
b Although these are denoted as ESBL positive, molecular characterization was not done; therefore, some strains may be K1 hyperproducers instead of ESBL
producers.
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3% lower than that of ESBL-negative isolates, representing a
smaller drop in activity than that observed with ertapenem.
Table 3 summarizes rates of ESBL-positive E. coli and K.
pneumoniae isolates from community-acquired and hospital-
acquired infections in the Asia-Pacific region overall, China,
India, and the Asia-Pacific region excluding those two coun-
tries. In the Asia-Pacific region excluding China and India,
ESBL-positive E. coli rates for community-acquired and hos-
pital-acquired infections were 13.7% and 31.5%, respectively.
China’s rates were roughly double those, at 36% and 64.7%,
respectively, but showed approximately the same overall ratio
of hospital-acquired infections to community-acquired infec-
tions: roughly twice as many hospital-acquired infections as
community-acquired infections. In India, however, the com-
munity-acquired-infection rate of 79.0% was virtually identical
to that of hospital-acquired infections (78.9%). ESBL-positive
FIG. 1. Frequency distribution of ESBL-positive isolates by country in the Asia-Pacific (AP) region during 2007. Korea refers to South
Korea.
TABLE 2. Antimicrobial susceptibilities of the eight most commonly isolated species to ertapenem, imipenem, and other comparator agents
Organism (no. of isolates)
% of isolates susceptible toa:
ETP IMP AK CPE CFT CFX CAZ CAX CP LVX P/T A/S
C. freundii (51) 98 100 84 71 43 16 43 45 71 77 71 37
E. aerogenes (65) 97 97 83 77 48 22 46 55 75 83 69 31
E. cloacae (150) 94 98 92 79 49 7 53 48 77 79 71 17
E. coli ESBL (578) 96 98 87 14* 5* 66* 29* 4* 17 21 83 5
E. coli ESBL (790) 99 100 98 99 97 89 95 96 70 72 94 43
K. oxytoca ESBL (22) 100b 100 86 41* 14* 64* 27* 9* 27 41 68 5
K. oxytoca ESBL (29) 100 100 100 100 97 97 97 97 93 97 100 76
K. pneumoniae ESBL (189) 86 97 73 28* 9* 61* 20* 10* 27 43 57 6
K. pneumoniae ESBL (339) 99 100 99 99 97 87 97 97 93 94 94 76
P. mirabilis (61) 100 100 92 87 77 95 89 77 69 84 97 72
P. aeruginosa (245) NA 71 85 69 14 NA 66 19 71 73 81 NA
a ETP, ertapenem; IMP, imipenem; AK, amikacin; CPE, cefepime; CFT, cefotaxime; CFX, cefoxitin; CAZ, ceftazidime; CAX, ceftriaxone; CP, ciprofloxacin; LVX,
levofloxacin; A/S, ampicillin-sulbactam; P/T, piperacillin-tazobactam. , CLSI standard M100-S17 recommends interpreting all cephalosporin results as resistant for
ESBL strains (4); NA, no CLSI breakpoint defined.
b While U.S. labels and prescribing information state that ertapenem and imipenem have been shown to be active against most strains of K. oxytoca both in vitro and
for clinical infections, there is a notation in the “Clinical pharmacology” section of the ertapenem label that this activity excludes ESBL-producing strains.
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K. pneumoniae rates for hospital-acquired infections were
three to four times higher than rates for community-acquired
infections, the exception again being India, with rates of 72.7%
and 61.8%, respectively.
DISCUSSION
Various country-based reports describing the incidence and
susceptibility of ESBL-positive isolates of GNB are available in
the literature, and each one reports quite different ESBL rates.
For example, a one-center study in Vietnam reported that, of
350 isolates from clinical specimens, 87.4% were GNB. Of
these GNB isolates, 88.9% were Enterobacteriaceae, of which
14.7% were ESBL positive (13). A study of 493 isolates from a
single center in South Korea of Enterobacter, Serratia marc-
escens, C. freundii, and Morganella morganii revealed rates of
ESBL-positive isolates of 12.8%, 12.4%, 4.9%, and 0%, respec-
tively (5). Ko et al., from South Korea, described 22.4% of K.
pneumoniae isolates and 10.2% of E. coli isolates as ESBL
producers (14). In a recent study from Taiwan, 28.4% of K.
pneumoniae isolates collected from various body sites were
ESBL positive (4). Furthermore, in a study from India the
percentage of ESBL-positive isolates was similarly elevated,
with 23.1% of isolates being ESBL positive (18). Of the isolates
from India, 48.4% of isolates were E. coli and 51.6% were K.
pneumoniae. Notably, all of the ESBL-producing isolates were
consistently susceptible only to carbapenems.
Asia is almost certainly a part of the world in which ESBLs
have emerged de novo, with early antimicrobial resistance
studies showing elevated levels of ESBL phenotypes, particu-
larly among Klebsiella isolates and particularly in China, South
Korea, Japan, and India (10). In most countries, there are
mixtures of CTX-M types, with VEB appearing significantly in
Vietnam and Thailand and ESBL isolates from India being
completely dominated by the presence of blaCTX-M-15 alone,
with no other CTX-M types reported (10). The data from the
SMART 2007 Asia-Pacific study show that E. coli and Kleb-
siella sp. ESBL frequencies are on the whole elevated in Asia
compared both to previous years (2) and other regions of the
world (2). Overall, ESBL frequencies in the Asia-Pacific region
from 2007 were 40% compared with 30%, 17%, 10%, and 8%
for Latin America, the Middle East and Africa, the European
Union, and North America, respectively (2). Moreover, ESBL
rates have markedly increased during the last few years in the
Asia-Pacific region, with ESBL rates rising steadily from 2003
(15%) to 40% in 2007 (2, 3). However, there are two major
features of the data from SMART 2007 (3) that are highly
noteworthy. The first is that this is the first study demonstrating
that, on the basis of the ESBL frequencies observed in India,
China, Thailand, and Vietnam, the ESBL-positive phenotype
has now become the dominant phenotype, alarmingly so in
India, with E. coli and K. pneumoniae ESBL rates of 79.0% and
69.4%, respectively. Furthermore, the ESBL-positive E. coli
rate in China was also notably high, running at 54.7%. India’s
near equivalence of rates of ESBL-positive isolates in commu-
nity- and hospital-acquired IAI of both E. coli and K. pneu-
moniae is particularly significant. Additionally, these high rates
were observed in all nine study centers in India, each repre-
senting distinct cities in various regions of India: New Delhi,
Lucknow, Indore, Mumbai, Hyderabad, Bangalore, Chennai,
Tamil Nadu, and Kolkata. The very high rates of ESBL-posi-
tive strains are seen all over the country and are not restricted
to any single city or region. ESBL-positive K. oxytoca rates
were also high in several countries. However, as molecular
characterization of the strains was not performed, we are not
able to distinguish K1-hyperproducing K. oxytoca from ESBL-
producing K. oxytoca.
With the combined populations of India and China being
circa 2.5 billion and with relatively high fecal carriage rates,
these countries represent major ESBL gene reservoirs. Second,
resistance to the majority of the antimicrobials used in the
SMART 2007 study was high, with the exception of the car-
bapenems ertapenem and imipenem. It is important to men-
tion, therefore, that, despite the high and increasing ESBL
rates within Asia, and in particular in India, China, Thailand,
and Vietnam, most ESBL-producing isolates remain suscepti-
ble to this important antibiotic class. Nevertheless, rates of
resistance to ertapenem and imipenem in the current SMART
study, albeit relatively low, may be creeping somewhat higher.
Since almost all diminished ertapenem activity occurred in K.
pneumoniae, we suspect it was due to the increasing incidence
of KPC-producing strains; however, since study strains prior to
2008 were not saved or sent to a central laboratory for further
testing, this supposition cannot be confirmed. Hence, further
in-depth studies such as SMART and others are highly war-
ranted in order to keep pace with the evolving clinical impor-
tance of ESBL producers and their susceptibility to currently
available agents.
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